How can transverse myelitis be differentiated from subacute combined degeneration?

Differentiating Transverse Myelitis from Subacute Combined Degeneration

The distinction between transverse myelitis and subacute combined degeneration hinges on three key features: time course (acute versus insidious), MRI pattern (central cord enhancement versus dorsal/lateral column T2-hyperintensity without enhancement), and laboratory findings (inflammatory CSF versus low B12 with normal CSF). 1

Time Course and Onset Pattern

• Transverse myelitis develops acutely to subacutely over hours to days, reaching maximal severity (nadir) within 2 weeks of symptom onset. 1
• Subacute combined degeneration presents insidiously over weeks to months with progressive, gradual worsening. 1
• This temporal distinction is the single most important clinical clue: if symptoms evolved to their worst point in less than 2 weeks, strongly favor transverse myelitis; if they crept in over many weeks, suspect SCD. 1

Neurological Examination Findings

Transverse Myelitis Pattern

• A distinct sensory level is typically present, with bilateral (though possibly asymmetric) motor weakness and sensory loss below that level. 1
• Bowel and bladder dysfunction appears early in the disease course. 1
• Reflexes are variable—initially decreased (spinal shock phase) or later hyperactive with upper motor neuron signs. 1
• Radicular or band-like pain is common and often prominent. 1

Subacute Combined Degeneration Pattern

• Sensory ataxia and gait disturbance dominate the early presentation due to dorsal column involvement (loss of proprioception and vibration sense). 1
• Pain and temperature sensation are typically preserved, while proprioception and vibration are severely impaired. 1
• Motor weakness develops later in the disease course, not as an early feature. 1
• Reflexes show a mixed pattern: absent ankle jerks with preserved or increased knee jerks, plus possible extensor plantar responses (Babinski sign). 1
• Paresthesias and numbness are prominent, but a sharp sensory level is absent. 1

MRI Findings: The Decisive Differentiator

Transverse Myelitis

• Lesions involve the central cord, affecting both gray and white matter. 1
• Lesion length is variable: short (< 3 vertebral segments) or longitudinally extensive (≥ 3 segments). 1, 2
• Gadolinium enhancement is common, indicating active inflammation. 1
• Cord swelling is frequently observed in the acute phase. 1
• Lesions can occur at any spinal level (cervical, thoracic, or lumbar). 1

Subacute Combined Degeneration

• Symmetric T2-hyperintensity confined exclusively to the dorsal and lateral columns—this is pathognomonic for SCD. 1, 2
• On axial cervical images, the pattern appears as an "inverted V" sign. 1, 2
• On axial thoracic images, the pattern appears as bilateral paired nodular hyperintensity resembling a "dumbbell" or "binoculars" sign. 1, 2
• No gadolinium enhancement is seen. 1
• No cord swelling is present. 1
• The selective tract involvement without central gray matter signal distinguishes SCD from inflammatory myelitis. 1

Laboratory Evaluation

Transverse Myelitis

• CSF pleocytosis and elevated protein occur in 50–70% of cases. 1
• Oligoclonal bands may be present, especially when demyelinating etiology (e.g., multiple sclerosis) is suspected. 1
• Autoimmune antibody testing (aquaporin-4 IgG for neuromyelitis optica, MOG antibodies) is recommended. 1
• Infectious workup (viral PCRs, bacterial cultures) should be performed when clinically indicated. 1

Subacute Combined Degeneration

• Low serum vitamin B12 (< 200 pg/mL) is the hallmark laboratory abnormality. 1
• Elevated methylmalonic acid (MMA) and homocysteine confirm functional B12 deficiency even when B12 levels are borderline (200–400 pg/mL). 1
• CSF is typically normal, which helps differentiate SCD from inflammatory myelitis. 1
• Macrocytic anemia may accompany SCD, but neurological symptoms often precede hematologic changes. 1

Diagnostic Algorithm

1. Assess time course: Acute onset (< 24 hours to 2 weeks) → transverse myelitis; subacute/chronic onset (weeks to months) → SCD. 1

2. Perform neurological examination:

   • Prominent sensory level with early motor weakness and bowel/bladder dysfunction → transverse myelitis. 1
   • Gait ataxia with loss of proprioception/vibration but preserved pain/temperature → SCD. 1

3. Obtain MRI with and without gadolinium:

   • Central cord T2-hyperintensity with gadolinium enhancement → transverse myelitis. 1
   • Symmetric dorsal/lateral column hyperintensity ("inverted V" or "dumbbell" sign) without enhancement → SCD. 1

4. If MRI suggests transverse myelitis:

   • Perform lumbar puncture for CSF analysis. 1
   • Order autoimmune antibody panel (aquaporin-4 IgG, MOG antibodies). 1
   • Consider infectious studies based on clinical context. 1

5. If MRI suggests SCD:

   • Order serum B12, MMA, homocysteine, and complete blood count. 1
   • CSF analysis is typically not needed unless the diagnosis remains uncertain. 1

Critical Pitfalls to Avoid

• Do not administer folic acid before excluding or treating B12 deficiency—this can precipitate or worsen SCD. 1
• Normal or borderline B12 levels (200–400 pg/mL) do not exclude SCD; up to 30% of patients require MMA/homocysteine testing for confirmation. 1
• Do not delay high-dose methylprednisolone in transverse myelitis—treatment should begin within hours of diagnosis, as delay worsens outcomes. 1
• A sharp sensory level raises suspicion for spinal cord pathology but does not differentiate the two conditions; MRI pattern is decisive. 1

Treatment Implications

Transverse Myelitis

• Immediate high-dose intravenous methylprednisolone (1–2 g daily for 3–5 days). 1
• Consider intravenous immunoglobulin (2 g/kg over 5 days) if steroids are contraindicated or response is inadequate. 1
• Plasma exchange is recommended for refractory cases. 1

Subacute Combined Degeneration

• Prompt vitamin B12 replacement is essential to prevent irreversible neurological damage. 1
• With neurological involvement: hydroxocobalamin 1 mg intramuscularly on alternate days until clinical improvement, then 1 mg every 2 months lifelong. 1
• Without neurological involvement: hydroxocobalamin 1 mg intramuscularly three times weekly for 2 weeks, then every 2–3 months lifelong. 1
• Urgent neurologist consultation is advised for any patient with neurological manifestations of SCD to prevent irreversible damage. 1